Share:
- PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) is the first oral therapy specifically designed to combat COVID-19 to be evaluated in a pediatric clinical study
- PAXLOVID is currently authorized under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) in both high-risk adult and high-risk pediatric patients 12 years of age and older weighing at least 40 kg
- Clinical data from the EPIC-HR study showed PAXLOVID reduced risk of hospitalization or death from any cause by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to placebo, with no deaths observed in the treatment group. Treatment-emergent adverse events were comparable between PAXLOVID (23%) and placebo (24%), most of which were mild in intensity.
Read the full press release here.
Source : Pfizer Inc.
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.